Blockade of SARS-CoV-2 spike protein-mediated cell–cell fusion using COVID-19 convalescent plasma

• Published in: Scientific reports Vol. 11; no. 1; pp. 5558 - 11
• Main Authors: Wang, Ling, Zhao, Juan, Nguyen, Lam N. T., Adkins, James L., Schank, Madison, Khanal, Sushant, Nguyen, Lam N., Dang, Xindi, Cao, Dechao, Thakuri, Bal Krishna Chand, Lu, Zeyuan, Zhang, Jinyu, Zhang, Yi, Wu, Xiao Y., El Gazzar, Mohamed, Ning, Shunbin, Moorman, Jonathan P., Yao, Zhi Q.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 10.03.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/250; 631/326; ACE2; Adult; Angiotensin-converting enzyme 2; Antibodies, Neutralizing - immunology; Antibodies, Viral - immunology; Cell fusion; Cell Fusion - methods; Coronaviruses; COVID-19; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 - therapy; COVID-19 Serotherapy; Effector cells; Female; Fusion protein; Humanities and Social Sciences; Humans; Immunization, Passive - methods; Immunoglobulin G; Infectious diseases; Male; Membrane fusion; Membrane Fusion - drug effects; Middle Aged; Molecular modelling; multidisciplinary; Pandemics; Pandemics - prevention & control; Plasma; Plasma - chemistry; Proteins; Public health; Receptors, Virus - metabolism; SARS-CoV-2 - immunology; SARS-CoV-2 - pathogenicity; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - immunology; Spike Glycoprotein, Coronavirus - metabolism; Spike protein; Virus Internalization - drug effects

The recent COVID-19 pandemic poses a serious threat to global public health, thus there is an urgent need to define the molecular mechanisms involved in SARS-CoV-2 spike (S) protein-mediated virus entry that is essential for preventing and/or treating this emerging infectious disease. In this study,...